Cocrystal Pharma, Inc.

Contributing Author

Recent Articles by Cocrystal Pharma, Inc.

Jun-05	Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference COCP GlobeNewswire
May-29	Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain COCP GlobeNewswire
May-28	Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference COCP GlobeNewswire
May-15	Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs COCP GlobeNewswire